|1.||Parker, William B: 4 articles (09/2006 - 03/2003)|
|2.||Someya, Hitoshi: 3 articles (06/2006 - 03/2003)|
|3.||Secrist, John A: 2 articles (09/2006 - 03/2003)|
|4.||Tiwari, Kamal N: 2 articles (09/2006 - 03/2003)|
|5.||Drolet, Daniel W: 2 articles (05/2006 - 03/2006)|
|6.||Hart, Karen: 2 articles (03/2006 - 03/2005)|
|7.||Tomkinson, Blake: 2 articles (03/2005 - 12/2004)|
|8.||Goss, G: 1 article (11/2006)|
|9.||Gauthier, I: 1 article (11/2006)|
|10.||Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group: 1 article (11/2006)|
11/01/2006 - "A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group."
11/01/2006 - "To determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety, tolerability, toxicity profile, dose-limiting toxicities (DLTs), anti-tumor activity and pharmacokinetics of OSI-7836 given IV on day 1 and day 8 every 3 weeks in patients with advanced incurable cancer. "
06/01/2006 - "Long intracellular retention of 4'-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4'-thio-arabinofuranosylcytosine."
03/01/2005 - "OSI-7836 (4'-thio-beta-D-arabinofuranosylcytosine) is a novel nucleoside analog in phase I clinical development for the treatment of cancer. "
12/15/2004 - "OSI-7836 (4'-thio-araC, T-araC) is a nucleoside analogue that shows efficacy against solid tumor xenograft models. "
05/01/2006 - "OSI-7836 was associated with excessive fatigue, and despite changes in its schedule and duration of administration, we did not observe an improvement in its tolerability. "
03/01/2006 - "These findings show a toxicological profile with OSI-7836 similar to other nucleoside analogues and suggest that the beagle is a model for studying one possible cause of OSI-7836-related fatigue, impaired function of the hypothalamic-pituitary-adrenal axis."
03/01/2006 - "Fatigue is also associated with the use of gemcitabine and OSI-7836 in humans. "
|2.||DNA (Deoxyribonucleic Acid)
|1.||Heterologous Transplantation (Xenotransplantation)